Metabolic Biomarkers of Liver Failure in Cell Models and Patient Sera: Toward Liver Damage Evaluation In Vitro

• Published in: International journal of molecular sciences 2024-12, Vol.25 (24), p.13739
• Main Authors: Rentschler, Simone, Doss, Sandra, Kaiser, Lars, Weinschrott, Helga, Kohl, Matthias, Deigner, Hans-Peter, Sauer, Martin
• Format: Article
• Language: English
• Subjects: Acute-On-Chronic Liver Failure - metabolism; Acute-On-Chronic Liver Failure - pathology; Adult; Analysis; Anidulafungin; Biological markers; Biomarkers; Cardiotoxicity; Caspofungin; Cell culture; Cells, Cultured; Chemical and Drug Induced Liver Injury - metabolism; Chemical and Drug Induced Liver Injury - pathology; Drugs; Failure; Female; Hepatitis; Hepatocytes - drug effects; Hepatocytes - metabolism; Humans; Ischemia; Liver; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver cirrhosis; Liver diseases; Liver failure; Liver Transplantation; Liver transplants; Male; Mass spectrometry; Medical prognosis; Metabolism; Metabolites; Metabolomics - methods; Middle Aged; Patients; Sufentanil; Toxicity; Toxins; Transplantation
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms252413739

Recent research has concentrated on the development of suitable in vitro cell models for the early identification of hepatotoxicity during drug development in order to reduce the number of animal models and to obtain a better predictability for hepatotoxic reactions in humans. The aim of the presented study was to identify translational biomarkers for acute liver injury in human patients that can serve as biomarkers for hepatocellular injury in vivo and in vitro in simple cell models. Therefore, 188 different metabolites from patients with acute-on-chronic liver failure before and after liver transplantation were analyzed with mass spectrometry. The identified potential metabolic biomarker set, including acylcarnitines, phosphatidylcholines and sphingomyelins, was used to screen primary and permanent hepatocyte culture models for their ability to model hepatotoxic responses caused by different drugs with known and unknown hepatotoxic potential. The results obtained suggest that simple in vitro cell models have the capability to display metabolic responses in biomarkers for liver cell damage in course of the treatment with different drugs and therefore can serve as a basis for in vitro models for metabolic analysis in drug toxicity testing. The identified metabolites should further be evaluated for their potential to serve as a metabolic biomarker set indicating hepatocellular injury in vitro as well as in vivo.